2,450 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by Drum Hill Capital LLC

Drum Hill Capital LLC bought a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,450 shares of the medical equipment provider’s stock, valued at approximately $219,000.

Several other large investors also recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $25,000. Kestra Investment Management LLC purchased a new position in shares of Lantheus during the 4th quarter worth approximately $27,000. Signaturefd LLC grew its holdings in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the period. UMB Bank n.a. grew its holdings in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after acquiring an additional 134 shares during the period. Finally, World Investment Advisors LLC purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $60,000. 99.06% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on LNTH. The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Truist Financial reissued a “buy” rating and issued a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $131.86.

Lantheus Trading Down 3.2 %

LNTH stock opened at $78.23 on Friday. The stock has a market capitalization of $5.44 billion, a PE ratio of 13.02 and a beta of 0.44. Lantheus Holdings, Inc. has a 12-month low of $56.44 and a 12-month high of $126.89. The stock’s 50 day simple moving average is $90.31 and its 200 day simple moving average is $97.06.

Insider Activity at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is currently owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.